BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 21635149)

  • 21. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
    Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiotoxicity of cytotoxic drugs.
    Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
    Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
    Johnson SA
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
    Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
    Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological foundations of cardio-oncology.
    Minotti G; Salvatorelli E; Menna P
    J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H; Coronado C
    Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
    Sadurska E
    Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
    Ghigo A; Li M; Hirsch E
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
    Menna P; Recalcati S; Cairo G; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthracycline associated cardiotoxicity in survivors of childhood cancer.
    Lipshultz SE; Alvarez JA; Scully RE
    Heart; 2008 Apr; 94(4):525-33. PubMed ID: 18347383
    [No Abstract]   [Full Text] [Related]  

  • 33. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
    Robinson EL; Azodi M; Heymans S; Heggermont W
    Curr Heart Fail Rep; 2020 Dec; 17(6):357-364. PubMed ID: 32964378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity of antitumor drugs.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2008 May; 21(5):978-89. PubMed ID: 18376852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthracycline cardiotoxicity after breast cancer treatment.
    Hershman DL; Shao T
    Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.